Advancing MS therapy: Addressing the patient experience

Chair and Faculty

Til Menge (Chair)
Center for Neurology and Neuropsychiatry
LVR-Clinic, Heinrich-Heine Hospital,
University of Düsseldorf, Düsseldorf, Germany

Anne-Katrin Pröbstel
Multiple Sclerosis Center, Neurologic Clinic and Policlinic,
Departments of Medicine, Biomedicine, and Clinical Research,
University Hospital of Basel, University of Basel, Basel, Switzerland

Bart Van Wijmeersch
Universitair MS Centrum (UMSC), Rehabilitation & MS Centre Overpelt,
Hasselt University, Hasselt, Belgium

Chair’s introduction:
Next steps for individualising MS care
Til Menge, Germany

Improving interferon beta further:
Intramuscular peginterferon beta-1a
Til Menge, Germany

Tailoring fumarates to advance clinically meaningful outcomes
Anne-Katrin Pröbstel, Switzerland

Enhancing convenience and flexibility with subcutaneous natalizumab
Bart Van Wijmeersch, Belgium

Audience Q&A
All faculty

Agenda

13:45
13:53
14:05
14:17
14:30

- Chair’s introduction: Next steps for individualising MS care
  Til Menge, Germany

- Improving interferon beta further: Intramuscular peginterferon beta-1a
  Til Menge, Germany

- Tailoring fumarates to advance clinically meaningful outcomes
  Anne-Katrin Pröbstel, Switzerland

- Enhancing convenience and flexibility with subcutaneous natalizumab
  Bart Van Wijmeersch, Belgium

- Audience Q&A
  All faculty

This symposium is organised and funded by Biogen Global Medical.
© 2021 Biogen. All rights reserved.

Satellite Symposium at the 7th EAN Congress

Register for EAN 2021